

## Diclofenac (Sodium)

**Catalog No: tcsc2355** 

Available Sizes

**Size:** 5g

Specifications

#### CAS No:

15307-79-6

Formula:

 $\mathsf{C}_{14}\mathsf{H}_{10}\mathsf{Cl}_2\mathsf{NNaO}_2$ 

**Pathway:** Immunology/Inflammation

**Target:** 

COX

**Purity / Grade:** 

>98%

### Solubility:

H2O : 10 mg/mL (31.43 mM; ultrasonic and warming and heat to 60°C)

#### Alternative Names: GP 45840

# **Observed Molecular Weight:** 318.13

### **Product Description**

Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a **COX** inhibitor, with  $IC_{50}$ s of 4 nM, 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1, 0.84  $\mu$ M for ovine COX-1 and COX-2, respectively.

IC50 & Target: IC50: 4 nM (Human COX-1, in CHO cells), 1.3 nM (Human COX-2, in CHO cells)<sup>[1]</sup>, 5.1  $\mu$ M (Ovine COX-1), 0.84  $\mu$ M (Ovine COX-2)<sup>[2]</sup>



In Vitro: Diclofenac Sodium (GP 45840) is a potent COX inhibitor, with  $IC_{50}$ s of 4 nM and 1.3 nM for human COX-1 and COX-2 in the CHO cells, respectively. Diclofenac effectively blocks COX-1 mediated prostanoid production from U937 cell microsomes, with an  $IC_{50}$  of 7 ± 3 nM<sup>[1]</sup>. Diclofenac Sodium exihibits inhibition on COX-1 and COX-2 enzyme with  $IC_{50}$ s of 5.1 and 0.84  $\mu$ M, respectively<sup>[2]</sup>.

*In Vivo:* Diclofenac (3 mg/kg, b.i.d., for 5 days) significantly increases faecal <sup>51</sup>Cr excretion in rats, and such effect is also observed in squirrel monkeys after administrated of 1 mg/kg twice daily for 4 days<sup>[1]</sup>. Diclofenac (10 mg/kg) shows anti-inflammatory activity in mice<sup>[2]</sup>. Diclofenac (10 mg/kg) decreases oxidized low-densitylipoprotein (Ox-LDL), but shows no effects on the kinetics parameters of catalase and glutathione peroxidase via intramuscularly injection into rats<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.